Caribou Biosciences
Caribou Biosciences raises $304M Series C at $1.2B valuation
Quick Facts
Caribou Biosciences: Series C Funding Round
Caribou Biosciences has successfully raised $304M in Series C funding, reaching a valuation of $1.2B.
Company Overview
CRISPR gene editing for cell therapies
Funding Details
The Series C round was led by RA Capital Management, with participation from Baillie Gifford, Redmile Group, Pfizer Ventures.
Company Information
- Headquarters: 2929 Seventh Street, Berkeley, CA 94710
- Founded: 2011
- Employees: 200+
- Category: Biotech
Investment
Caribou Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- RA Capital Management: Verified investor in Series C
- Baillie Gifford: Verified investor in Series C
- Redmile Group: Verified investor in Series C
- Pfizer Ventures: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...